alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### THE STATE TO THE USE OF WILLIS F. REDDICK *vs.*GEORGE W. B. SATTERFIELD.

'An infant, being entitled to a sum of money arising from the sale of a tract of land, sold under a decree of a Court of Equity, and the same having been received by her guardian, conveyed it by a deed of trust to her separate use, and if she died without leaving a child, to her intended husband. She married and died under age and without a child. *Held,*that in a Court of Law, at least, her personal representative was entitled to recover the money so receivod by the guardian.

Appeal from the Superior Court of Law of Gates County, at the Spring Term 1849, his Honor Judge Manly presiding.

This was an action of debt on a guardian bond. Sarah Ann Hunter, the intestate of the plaintiff, and the ward of the defendant, in 1S47, before her marriage, executed a deed, conveying all her estate, among other things the proceeds of the sale of a tract of land, sold under the decree of the Court of Equity for partition, which was in the hands of the defendant, her guardian, to a trustee for her separate use, and if she died without a child living at her death, then to the use of her contemplated husband, one Willis F. Riddick.

*359The intestate intermarried with the said Riddick, and had a child born alive, but it died before the intestate. At the date of the deed and at the time of her marriage, the intestate was about sixteen years of age. She died at the age of eighteen.

The breach assigned was a refusal to pay the amount of about $1000, the sum received by the defendant, as guardian, together with interest thereon from the 19th of May, 1840; at which time, the defendant, as guardian, 'had received the said amount, being his ward’s share of the land, sold under the decree of the Court of Equity, for partition.

His Honor was of opinion, that the plaintiff could only recover the interest upon the sum received by the defendant, as guardian ; and a verdict and judgment were en' tered for the plaintiff for the penalty of the bond, to be discharged by the payment of the sum of $549, which was the interest upon the sum received by the defendant.

*Heath,*for the plaintiff.

No counsel for the defendant.

Pearson, J.

We think his Honor was mistaken in the view, which he took of the case. Admit that the deed of the intestate was void by reason of her infancy, his Honor seems to have been under the impression, that the fund was to be treated as land, and that the plaintiff, as personal representative, could only recover the profits or interest up to the time of the death of the intestate, which, we presume, he considered was for the benefit of the husband, but that the principal belonged to the heirs at law.

Without deciding how the rights of the parties may be considered in a Court of Equity, we are of opinion, that in a *Court of Law,*the defendant, having received money belonging to his ward, was, after her death, bound to pay it over to her personal representative-; and that his re*360fusal to do so was a clear breach of the bond to the amount of *principal*and interest.

The judgment must be set aside and a *venire de no,vo*issued.

Pek. CuRiam. Judgment accordingly.
Exhibit
10.95


 





 


October
21, 2020


 


Yash
Thukral


16911
San Fernando Mission Boulevard, Suite #183


Granada
Hills, CA 91344


 


Re:   Equity
Purchase Agreement


 


Dear
Yash:


 


Reference
is made to that certain Equity Purchase Agreement (the “Purchase Agreement”), by and between White Lion Capital,
LLC (“White Lion”) and RespireRx Pharmaceuticals Inc. (“RSPI”), dated July 28, 2020. Capitalized
terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement.


 


The
purpose of this letter is to clarify between the parties that the minimum price per share at which shares of Common Stock will
be purchased under the Purchase Agreement shall be the par value of such shares.


 


1.
Accordingly, for purposes of calculating the Investment Amount under Section 2.2(d)(ii), the parties hereto hereby acknowledge
and agree that, if the terms of Section 2.2 of the Purchase Agreement would result in the Purchase Price being equal to less than
$0.001, then, notwithstanding that result, the Purchase Price shall be an amount equal to $0.001; provided, however, in such case
White Lion may at its option elect to return the applicable Purchase Notice Shares to the Company, and the Company agrees to release
the funds deposited into the Escrow Account in respect of such Purchase Notice Shares to White Lion.


 


2.
RSPI hereby represents, covenants and agrees that it shall not deliver a Purchase Notice under Section 2.2(a) of the Purchase
Agreement if, as of the end of the most recent Trading Day, the closing share price for the Common Stock on any Principal Market
was less than $0.001177.


 


3.
White Lion hereby represents, covenants and agrees that it shall not, prior to any Closing Date, re-sell any Purchase Notice Shares
to be paid for on such Closing Date at a price less than $0.001.


 


If
this accurately reflects our mutual understanding, please kindly confirm by executing this letter in the space provided below
and returning to the undersigned.


 


[Signatures
follow]


 


RespireRx
Pharmaceuticals Inc., 126 Valley Road, Suite C, Glen Rock, NJ 07452


 




    	 



     


    

 





 


	 	Sincerely,
	 	 
	 	RESPIRERX
    PHARMACEUTICALS INC.
	 		
	 	By:	/s/
    Jeff Margolis
	 	Name:	Jeff
    E. Margolis
	 	Title:
    	Senior
    Vice President, Chief Financial
	 	 	Officer,
    Treasurer and Secretary


 


	Accepted
    and agreed to by:	 
	 	 	 
	WHITE
    LION CAPITAL LLC	 
	 	 	 
	By:	/s/
    Yash Thukral	 
	Name:
    	Yash
    Thukral	 
	Title:	Manager	 


 


RespireRx
Pharmaceuticals Inc., 126 Valley Road, Suite C, Glen Rock, NJ 07452
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 02-10559 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus MARIA MARTHA CHAVEZ-GUIDO, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Northern District of Texas USDC No. 6:01-CR-61-ALL-C

-------------------- October 30, 2002 Before DeMOSS, BENAVIDES, and STEWART, Circuit Judges. PER CURIAM: * Maria Martha Chavez-Guido appeals the sentence imposed following her guilty plea conviction of being found in the United States after deportation in violation of 8 U.S.C. § 1326. Chavez-Guido contends that 8 U.S.C. § 1326(a) and 8 U.S.C. § 1326(b)(2) define separate offenses. She argues that the aggravated felony conviction that resulted in her increased sentence is an element of the offense under 8 U.S.C. § 1326(b)(2) that should have been alleged in her indictment. Chavez-Guido maintains that she pleaded guilty to an indictment which chargedNo. 02-10559 -2- only simple reentry under 8 U.S.C. § 1326(a). She argues that her sentence exceeds the two-year maximum term of imprisonment which may be imposed for that offense.
In Almendarez-Torres v. United States , 523 U.S. 224, 235 (1998), the Supreme Court held that the enhanced penalties in 8 U.S.C. § 1326(b) are sentencing provisions, not elements of separate offenses. The Court further held that the sentencing provisions do not violate the Due Process Clause. Id. at 239-47. Chavez-Guido acknowledges that her argument is foreclosed by Almendarez-Torres , but asserts that the decision has been cast into doubt by Apprendi v. New Jersey , 530 U.S. 466, 490 (2000). She seeks to preserve her argument for further review. Apprendi did not overrule Almendarez-Torres

. See Apprendi , 530 U.S. at 489-90; United States v. Dabeit , 231 F.3d 979, 984 (5th Cir. 2000), cert. denied , 531 U.S. 1202 (2001). This court must follow Almendarez-Torres “unless and until the Supreme Court itself determines to overrule it.” Dabeit , 231 F.3d at 984 (internal quotation marks and citation omitted). The judgment of the district court is AFFIRMED. In lieu of filing an appellee’s brief, the Government has filed a motion asking this court to dismiss this appeal or, in the alternative, to summarily affirm the district court’s judgment. The Government’s motion to dismiss is DENIED. The motion for a summary affirmance is GRANTED. The Government need not file an appellee’s brief. AFFIRMED; MOTION TO DISMISS DENIED; MOTION FOR SUMMARY AFFIRMANCE GRANTED.
Electronically Filed

Intermediate Court of Appeals

CAAP-16-0000545

26-MAY-2017

07:59 AM
**Exhibit 32.1**

**CERTIFICATION OFCHIEF EXECUTIVE OFFICER PURSUANT TO18 U.S.C. SECTION 1350**

In connection withthe Quarterly Report of Zoran Corporation (the “Company”) on Form 10-Q for theperiod ended September 30, 2006, as filed with the Securities and ExchangeCommission on the date hereof (the “Report”), I, Levy Gerzberg, President andChief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C.Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Actof 2002, that:

(1)   The Report fully complies with therequirements of Section 13(a) of the Securities Exchange Act of 1934; and

(2)   The information contained in the Reportfairly presents, in all material respects, the financial condition and resultof operations of the Company.

 
| Dated: April 19, 2007 |   | /s/ Levy Gerzberg                     |
|----------------------------|--------|---------------------------------------|
|                       |   | Levy Gerzberg                         |
|                       |   | President and Chief Executive Officer |

 

----
##### 



Exhibit 15 May 2, 2005 Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549 RE: Tollgrade Communications, Inc.  1)
    Form S-8 (Registration No. 333-4290, 333-65502, and
333-83007 and 333-95965) 1995 Long-Term
Incentive Compensation Plan and Individual Stock Options Granted to Certain Directors and
Employees Prior to the Adoption of the Plan  2)
    Form S-8 (Registration No. 333-52907 , 333-55470
and 333-096969) 1998 Employee
Incentive Compensation Plan Commissioners: We are aware that our report dated May 2, 2005 on our review of interim financial information of
Tollgrade Communications, Inc. for the three month period ended March 26, 2005 and March 27, 2004
and included in the Companys quarterly report on Form 10-Q for the quarter ended March 26, 2005 is
incorporated by reference in its Registration Statements referred to above. Very truly yours, /s/ PricewaterhouseCoopers LLP PricewaterhouseCoopers LLP 41
I 

115TH CONGRESS 

1ST SESSION H. R. 1705 

To amend the Immigration and Nationality Act to modify the provisions 

governing employment of nonimmigrants under section 

101(a)(15)(H)(i)(b) of that Act to prevent the transfer of knowledge 

from United States workers for the purpose of facilitating their jobs 

being moved abroad. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 23, 2017 

Mr. KILMER (for himself and Mr. COLLINS of Georgia) introduced the 

following bill; which was referred to the Committee on the Judiciary 

A BILL 

To amend the Immigration and Nationality Act to modify 

the provisions governing employment of nonimmigrants 

under section 101(a)(15)(H)(i)(b) of that Act to prevent 

the transfer of knowledge from United States workers 

for the purpose of facilitating their jobs being moved 

abroad. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Keeping American 

5 Jobs Act’’. 


lotter on DSK5VPTVN1PROD with BILLS
2 

•HR 1705 IH

1 SEC. 2. PREVENTING DISPLACEMENT OF UNITED STATES 

2 WORKERS. 

3 Section 212(n)(1)(E)(ii) of the Immigration and Na4 tionality Act (8 U.S.C. 1182(n)(1)(E)(ii)) is amended by 

5 inserting after the first sentence the following: ‘‘An appli6 cation is described in this clause if the Secretary of Labor 

7 determines that it was filed by an employer for the pri8 mary purpose of using one or more United States workers 

9 to train the H–1B nonimmigrant workers sought in the 

10 job duties and responsibilities of the United States work11 ers in order to lay off the United States workers and move 

12 their job or jobs abroad.’’. 

Æ 


lotter on DSK5VPTVN1PROD with BILLS
No. 90-6384.

#### Snyder *v.*United States.

C. A. 6th Cir. Certiorari denied.
HomeNRC LibraryDocument CollectionsNUREG-Series PublicationsPublications Prepared by NRC Contractors

# Pretest Round Robin Analysis of a Prestressed Concrete Containment Vessel Model (NUREG/CR-6678)

On this page:
        - Publication Information
        - Abstract

Download complete document
        - NUREG/CR-6678            - Cover – Appendix H (PDF - 14.60 MB)
          - Appendix I – End (PDF - 21.43 MB) 

## Publication Information

**Manuscript Completed:** June 2000**Date Published:** August 2000

**Prepared by:** V.K. Luk

Sandia National Laboratories Albuquerque, NM 87185-0744

**Prepared for:** Office of Nuclear Regulatory Research U.S. Nuclear Regulatory Commission****Washington, DC 20555-0001

NRC Job Code Extreme Loads JCN A1401

NRC Project Manager: J.F. Costello

Systems Safety Department Nuclear Power Engineering Corporation Tokyo 105, Japan Under Funds-in-Agreement No. DE-F104-91AL73734

NUPEC Project Manager: S. Shibata

Availability Notice

## Abstract

The Nuclear Power Engineering Corporation of Japan and the U.S. Nuclear Regulatory Commission, Office of Nuclear Regulatory Research, are co-sponsoring and jointly funding a Cooperative Containment Research Program at Sandia National Laboratories in Albuquerque, New Mexico. As a part of the program, a prestressed concrete containment vessel model will be tested to failure at Sandia in September 2000. The model, uniformly scaled at 1:4, is representative of the containment structure of an actual pressurized-water reactor plant (OHI-3) in Japan. The objectives of the internal pressurization test are to obtain data on the structural response of the model to pressure loading beyond design basis accident in order to validate analytical modeling, to find the model's pressure capacity, and to observe its response and failure mechanisms.

Seventeen organizations participated in a pretest Round Robin analysis to predict the structural response of the model under overpressurization. Each organization was supplied with the same basic information to use in its analysis. This information included the design drawings of the prestressed concrete containment vessel model and the material properties of the structural components. Each organization worked independently, using its own analytical methods, to produce analysis results for 55 specified locations on the model. The Round Robin analysis provides a forum for participants to discuss pretest predictions of the deformation behavior of the prestressed concrete containment vessel model, as well as to compare them to the test data.

This report contains the analytical modeling procedures and the pretest predictions submitted by each organization. This report also includes composite plots of participants' analysis results at the 55 specified locations on the model. These plots, which were discussed among participants at the pretest analysis meeting, held October 12-14, 1999, in Albuquerque, will be compared to the test data generated during the internal pressurization test.

Page Last Reviewed/Updated Wednesday, March 24, 2021
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                          17,001
<SECURITIES>                                    13,001
<RECEIVABLES>                                   82,617
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               124,882
<PP&E>                                          72,753
<DEPRECIATION>                                  40,644
<TOTAL-ASSETS>                                 179,396
<CURRENT-LIABILITIES>                           53,937
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         2,222
<OTHER-SE>                                     118,571
<TOTAL-LIABILITY-AND-EQUITY>                   179,396
<SALES>                                              0
<TOTAL-REVENUES>                                57,674
<CGS>                                                0
<TOTAL-COSTS>                                   52,192
<OTHER-EXPENSES>                                    41
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  86
<INCOME-PRETAX>                                  5,786
<INCOME-TAX>                                     2,314
<INCOME-CONTINUING>                              3,472
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,472
<EPS-PRIMARY>                                      .16
<EPS-DILUTED>                                      .16
        

</TABLE>
I 

115TH CONGRESS 

1ST SESSION H. R. 1855 

To repeal the authorizations for office space, office expenses, franking and 

printing privileges, and staff for former Speakers of the House of Representatives. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 3, 2017 

Mr. JONES (for himself and Mr. MASSIE) introduced the following bill; which 

was referred to the Committee on House Administration 

A BILL 

To repeal the authorizations for office space, office expenses, 

franking and printing privileges, and staff for former 

Speakers of the House of Representatives. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. REPEAL OF AUTHORIZATIONS FOR FORMER 

4 SPEAKERS. 

5 (a) REPEAL OF AUTHORIZATIONS FOR OFFICE

6 SPACE, OFFICE EXPENSES, FRANKING AND PRINTING

7 PRIVILEGES, AND STAFF.—The first section and sections 

8 2, 4, 5, and 8 of House Resolution 1238, Ninety-first Con9 gress, agreed to December 22, 1970 (as enacted into perVerDate Sep 11 2014 02:08 Apr 08, 2017 Jkt 069200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1855.IH H1855

lotter on DSK5VPTVN1PROD with BILLS
2 

•HR 1855 IH

1 manent law by chapter VIII of the Supplemental Appro2 priations Act, 1971) (2 U.S.C. 5125(a), 5126, 5127, 

3 5128, and 5129) are repealed. 

4 (b) CONFORMING AMENDMENT.—Subsection (b) of 

5 the first section of Public Law 93–532 (2 U.S.C. 5125(b)) 

6 is repealed. 

7 (c) EFFECTIVE DATE.—The amendments made by 

8 this Act shall apply with respect to any individual who 

9 is a former Speaker of the House of Representatives at 

10 any time before, on, or after the date of the enactment 

11 of this Act. 

Æ 


lotter on DSK5VPTVN1PROD with BILLS
[Federal Register Volume 80, Number 16 (Monday, January 26, 2015)]
[Notices]
[Page 3988]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-01287]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Manufacturer of Controlled Substances Registration: S & B Pharma, 
Inc.

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: S & B Pharma, Inc. applied to be registered as a manufacturer 
of certain basic classes of controlled substances. The DEA grants S & B 
Pharma, Inc. registration as a manufacturer of those controlled 
substances.

SUPPLEMENTARY INFORMATION: By notice dated July 1, 2014, and published 
in the Federal Register on July 8, 2014, 79 FR 38564, S & B Pharma, 
Inc., DBA Norac Pharma, 405 South Motor Avenue, Azusa, California 
91702-3232 applied to be registered as a manufacturer of certain basic 
classes of controlled substances. No comments or objections were 
submitted to this notice.
    The Drug Enforcement Administration (DEA) has considered the 
factors in 21 U.S.C. 823(a) and determined that the registration of S & 
B Pharma, Inc. to manufacture the basic classes of controlled 
substances is consistent with the public interest and with United 
States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971. The DEA investigated the company's 
maintenance of effective controls against diversion by inspecting and 
testing the company's physical security systems, verifying the 
company's compliance with state and local laws, and reviewing the 
company's background and history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above-named company is granted registration as a bulk 
manufacturer of the basic classes of controlled substances listed:

------------------------------------------------------------------------
            Controlled Substance                       Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)...........  I
Tetrahydrocannabinols (7370)...............  I
Methamphetamine (1105).....................  II
Pentobarbital (2270).......................  II
Nabilone (7379)............................  II
4-Anilino-N-phenethyl-4-piperidine (ANPP)    II
 (8333).
Tapentadol (9780)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for use in product development and for commercial sales to its 
customers.

    Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-01287 Filed 1-23-15; 8:45 am]
BILLING CODE P
**Exhibit 99.1**

 

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the quarterly report of Pharmaceutical Product Development, Inc. (“PPD”) on Form 10-Q for the period ended March 31, 2003 asfiled with the Securities and Exchange Commission on the date hereof (the “Report”), I, Fredric N. Eshelman, Chief Executive Officer of PPD, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that to my knowledge: 

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and 

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations ofPPD as of, and for, the periods presented in the Report. 

 

Date: May 9, 2003